207 related articles for article (PubMed ID: 6890825)
1. Cardiac action of KB-944, a new calcium antagonist.
Morita T; Ito K; Nose T
Arzneimittelforschung; 1982; 32(9):1053-5. PubMed ID: 6890825
[TBL] [Abstract][Full Text] [Related]
2. Vasodilator action of KB-944, a new calcium antagonist.
Morita T; Yoshino K; Kanazawa T; Ito K; Nose T
Arzneimittelforschung; 1982; 32(9):1037-42. PubMed ID: 6890822
[TBL] [Abstract][Full Text] [Related]
3. Effects of the new calcium antagonist monatepil on cardiac function and myocardial oxygen supply and demand in animals.
Kataoka T; Nose I; Honda Y; Yamada T; Hatano N; Masuda Y; Hosoki K; Karasawa T
Arzneimittelforschung; 1993 Dec; 43(12):1303-9. PubMed ID: 8141817
[TBL] [Abstract][Full Text] [Related]
4. Vasodilator mechanism of KB-944, a new calcium antagonist.
Morita T; Kanazawa T; Ito K; Nose T
Arzneimittelforschung; 1982; 32(9):1043-6. PubMed ID: 6890823
[TBL] [Abstract][Full Text] [Related]
5. Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine, and verapamil. A comparative study of physiological responses and membrane receptor activity.
Millard RW; Grupp G; Grupp IL; DiSalvo J; DePover A; Schwartz A
Circ Res; 1983 Feb; 52(2 Pt 2):I29-39. PubMed ID: 6831652
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular actions of the dihydropyridine calcium antagonist nimodipine in the dog.
Satoh K; Kawada M; Wada Y; Taira N
Arzneimittelforschung; 1984; 34(5):563-8. PubMed ID: 6540573
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of bepridil, diltiazem, nifedipine and verapamil on haemodynamic parameters and myocardial oxygen consumption in anaesthetized dogs.
Beaughard M; Michelin MT; Tisne-Versailles J; Lamar JC
Arch Int Pharmacodyn Ther; 1986 Dec; 284(2):276-96. PubMed ID: 3493742
[TBL] [Abstract][Full Text] [Related]
8. Antiarrhythmic effect of KB-944, a new calcium antagonist. A comparison with verapamil and diltiazem.
Yoshidomi M; Sukamoto T; Morita T; Ito K; Nose T
Arzneimittelforschung; 1982; 32(9):1056-9. PubMed ID: 6890826
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of new ethylenediamine derivatives (ROM-126, ROM-131, MK-142) with antiarrhythmic action. Part II. Antiarrhythmic properties, the influence on heart and some hemodynamic parameters.
Ernest K
Pol J Pharmacol Pharm; 1975; 27(4):381-98. PubMed ID: 1166019
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs.
Damiano BP; Giardino EC; Haertlein BJ; Stump GL; Mitchell JA; Falotico R
J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761
[TBL] [Abstract][Full Text] [Related]
11. [Calcium-antagonist-type cardiac effects of nifedipine in vitro and in vivo. Comparative experimental study].
Cosín J; Gimeno JV; Martín G; Ramírez A; Ferrer J; Báguena J
Rev Esp Cardiol; 1982; 35(5 Suppl 2):II115-22. PubMed ID: 7170402
[No Abstract] [Full Text] [Related]
12. Calcium-antagonist effects of norbormide on isolated perfused heart and cardiac myocytes of guinea-pig: a comparison with verapamil.
Bova S; Cargnelli G; D'Amato E; Forti S; Yang Q; Trevisi L; Debetto P; Cima L; Luciani S; Padrini R
Br J Pharmacol; 1997 Jan; 120(1):19-24. PubMed ID: 9117093
[TBL] [Abstract][Full Text] [Related]
13. Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms.
Millard RW; Lathrop DA; Grupp G; Ashraf M; Grupp IL; Schwartz A
Am J Cardiol; 1982 Feb; 49(3):499-506. PubMed ID: 6277175
[TBL] [Abstract][Full Text] [Related]
14. Cardiac versus coronary vasodilator actions of KB-944, a new calcium antagonist, assessed in isolated, blood-perfused heart preparations of dogs.
Taira N; Kawada M; Satoh K
J Cardiovasc Pharmacol; 1983; 5(3):349-56. PubMed ID: 6191131
[TBL] [Abstract][Full Text] [Related]
15. Cardiac and systemic hemodynamic actions of the slow channel calcium blocking agent, KB-944.
Pelc LR; Gross GJ; Warltier DC
Gen Pharmacol; 1985; 16(6):585-90. PubMed ID: 4085780
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular actions of 5,6-dimethoxy-2-(3-[(alpha-(3,4-dimethoxy) phenylethyl)-methylamino] propyl) phthalimidine (AQ-A 39), a specific bradycardic agent.
Dämmgen J; Kadatz R; Diederen W
Arzneimittelforschung; 1981; 31(4):666-70. PubMed ID: 7195712
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of OPC-13340, a potent, long-acting 1,4-dihydropyridine calcium channel blocker, in dogs.
Mori T; Nakayama N; Ohura M; Ikezono K; Kinoshita S; Kamata M; Hosokawa T; Yamashita S; Yabuuchi Y
Arch Int Pharmacodyn Ther; 1993; 321():41-56. PubMed ID: 8323415
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular profiles of the calcium antagonists nisoldipine and nifedipine in the blood-perfused dog heart.
Takahashi K; Taira N
Arzneimittelforschung; 1986 Jul; 36(7):1054-9. PubMed ID: 3768072
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of a new dihydropyridine calcium antagonist.
Kimura Y; Fukui H; Tanaka M; Okamoto M; Miura A; Kimura K; Enomoto H
Arzneimittelforschung; 1986 Sep; 36(9):1336-44. PubMed ID: 3790183
[TBL] [Abstract][Full Text] [Related]
20. [Hemodynamic and coronary effects of intravenous verapamil in coronary insufficiency].
Zygelman M; Mérillon JP; Guiomard A; Eustigneff T; Zannier D; Gourgon R
Arch Mal Coeur Vaiss; 1981 Jun; 74(6):685-94. PubMed ID: 6794490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
